Stonvex
Discover
  • Dashboard
  • World News
  • Stock News
  • Rankings
  • Quant Picks
  • Screener
Markets
  • Heatmap
  • Gainers & Losers
Tools
  • Compare
  • Calendar
  • Community
HomeRankingsScreenerPortfolioCommunity
Stonvex
Log inGet Started
← Back to search

RVMD

Live
Real-time chart · IB-grade AI research · Polygon.io data feed
Set alertSave
  • Overview
  • Financials
  • Filings
  • Short Interest
  • Ownership
  • Ratings
  • Peers
  • Options
  • News
✦
Stonvex AI

RVMD

AI Research Report

Powered by Claude

Ready to analyze RVMD

Runs the full IB-grade framework: Narrative, Reverse DCF, Comps, Sensitivity, and Deal Radar. Takes 20–40 seconds.

Free preview · 3 reports / hour · No sign-up required

Earnings

Next report date, year-over-year trend, and recent quarter history.

Earnings history activates with Polygon. When configured, this panel shows the next report date, consensus EPS/revenue, and the last 4 quarters of actual-vs-estimate.

Quant Grades

6-factor scoring with sector-relative rank. Updated daily.

Quant grades are available for tickers in our scored universe.

Financial statements

Most recent quarterly filings sourced directly from SEC EDGAR.

Financial statements activate with Polygon. The Developer plan includes quarterly and annual filings sourced directly from SEC EDGAR.

Corporate events

Share this analysis

Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.

Stonvex

AI-powered stock research for US equities.

hello@stonvex.com

Product

  • Rankings
  • Quant Picks
  • Screener
  • Markets
  • Compare
  • Calendar

Company

  • About Stonvex
  • Pricing & Plans
  • Community
  • Help & FAQ
  • Contact Us

Legal

  • Terms of Service
  • Privacy Policy
  • Privacy Consent
  • Disclaimer
  • Notices & Updates

© 2026 Stonvex. All rights reserved.

This site is for informational purposes only. Not investment advice. Past performance does not guarantee future results. Stonvex is not a registered investment advisor (RIA). You must be 18 years or older to use this service.

Latest news

Factor Grades

5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.

📅 Earnings in 26d (May 11)

Analyst Consensus

Buy
Based on 27 analysts
Period: 2026-04-01
26 Buy (96%)1 Hold (4%)0 Sell (0%)
Rating Distribution
Strong Buy
11
Buy
15
Hold
1
Sell
0
Strong Sell
0
Trend
2026-04
26/1/0
2026-03
26/1/0
2026-02
26/1/0
2026-01
26/1/0

Factor Grades

View details →
C
Overall score: 53/100
D-
Valuation
C
Growth
F
Profitability
A-
Momentum
A
Financial Health
Revolution Medicines Inc

Revolution Medicines Inc

Biotechnology·NASDAQ NMS - GLOBAL MARKET·US·IPO 2020-02-13
NASDAQ NMS - GLOBAL MARKETMarket closed
Revolution Medicines Inc
Biotechnology
$147.01
$10.71 (+7.86%)
Open
$136.50
Prev close
$136.30
Day range
$134.66 – $148.00
52W range
$32.16 – $136.80
Mkt cap
$29.13B
P/E
—
EPS
$-4.80
Beta
1.28

Fundamentals

Valuation
Market Cap
$29.13B
P/E (TTM)
—S&P avg ~22
P/S (TTM)
2334.17S&P avg ~2.8
P/B
9.44S&P avg ~4.5
P/FCF
—S&P avg ~26
EPS (TTM)
$-4.80
Book/sh
$8.28
Cash/sh
$10.28
Profitability
Gross Margin
—avg ~45%
Operating Margin
-3145.03%avg ~15%
Net Margin
-2833.88%avg ~12%
ROE
-54.06%avg ~18%
ROA
-39.14%avg ~7%
ROI
-46.96%
Payout Ratio
—
FCF/sh
—
Growth & Health
Rev Growth YoY
—
Rev Growth 5Y
—
EPS Growth YoY
—
EPS Growth 5Y
—
Current Ratio
—
Quick Ratio
6.97
Debt/Equity
—
LT Debt/Eq
—
Trading & Dividends
Beta
1.28
52W High
$136.80
52W Low
$32.16
Avg Vol (10D)
3.05M
Avg Vol (3M)
3.07M
Div Yield
—
Div/sh (TTM)
—
Analyst
Buy (27)
Price Performance
5D+41.55%
MTD+40.15%
3M+26.92%
6M+192.61%
YTD+71.12%
1Y+304.81%
  • SeekingAlpha·9h ago

    Revolution Medicines: 'Strong Buy' On Daraxonrasib Win And Expansions Underway

    Read the latest analysis on Revolution Medicines (RVMD) stock here.

  • Benzinga·9h ago

    Revolution Medicines shares are trading higher after multiple analysts raised their respective price targets on the stock.

  • SeekingAlpha·10h ago

    Johnson & Johnson Q2 Earnings Review: Why You Should Be Buying The Stock Today

    Johnson & Johnson’s strong Q1 lifts 2026 sales guidance above $100B; see product growth, pipeline catalysts, and key risks. Click for why JNJ stock is a Buy.

  • Benzinga·13h ago

    Wells Fargo Maintains Overweight on Revolution Medicines, Raises Price Target to $167

    Wells Fargo analyst Eva Fortea Verdejo maintains Revolution Medicines (NASDAQ:RVMD) with a Overweight and raises the price target from $144 to $167.

  • Benzinga·13h ago

    RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $162

    RBC Capital analyst Leonid Timashev maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $140 to $162.

  • Benzinga·14h ago

    Wedbush Reiterates Outperform on Revolution Medicines, Maintains $147 Price Target

    Wedbush analyst Robert Driscoll reiterates Revolution Medicines (NASDAQ:RVMD) with a Outperform and maintains $147 price target.

  • Benzinga·15h ago

    Guggenheim Maintains Buy on Revolution Medicines, Raises Price Target to $175

    Guggenheim analyst Michael Schmidt maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $160 to $175.

  • Benzinga·15h ago

    Evercore ISI Group Maintains Outperform on Revolution Medicines, Raises Price Target to $200

    Evercore ISI Group analyst Cory Kasimov maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $140 to $200.

  • View all news →
⚠️
Dilution risk detected

3 offering-related filings in the last 60 filings. Latest: 424B5 on 2026-04-13. View all →

Recent insider activity

View all →
  • 4Insider transaction
    20d ago
  • 4Insider transaction
    27d ago
  • 4Insider transaction
    27d ago
  • 4Insider transaction
    27d ago
  • 4Insider transaction
    27d ago